0.90 USD
▼-0.08-8.15%
盘后 0.93 +3.08%
2026-11-20
市值
$5.89M
市盈率
—
EPS
-1.30
股息率
—
52 周区间
0.78 – 9.48
成交量
32.14K
Beta
3.74
目标价
—
52W 低 0.7852W 高 9.48
价格走势
公司简介
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.